Home / Archives for EPTRIAdmin

Hospital Exemption in ATMP development

Within the Revision of the EU general pharmaceuticals legislation, we call for the European Commission to maintain a strong focus on the societal aim of health equity and to further support our researchers, clinicians, and hospital pharmacists in their various roles...

read more

EPTRI’s nomination to the TRANSFORM Steering Group

EPTRI is honored to announce its Giovanni Migliaccio’s nomination to represent the research stakeholder group within the TRANSFORM Steering Group.    EPTRI will contribute with its pivotal knowledge by representing the academic research perspective. EPTRI will support...

read more

EPTRI’s Special issue on Frontiers in Paediatrics

We are happy to introduce our Research topic on Frontiers in Paediatrics "Supporting the Pediatric Drug Development: From Basic Research to Clinical Studies and Technological Advancements". It is cross listed in other three Frontiers Journals and it is available...

read more

The ENCePP 2022 report is out!

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) report for 2022 is now available.   The ENCePP® is a network coordinated by the European Medicines Agency (EMA). The members of this network (the partners) are public institutions...

read more

A new indication on for Fintepla

The European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a new indication for Fintepla (fenfluramine).   Fintepla was indicated for the treatment of seizures associated with Dravet syndrome and now it will also be...

read more